Valeant's (VRX) Buy Rating Affirmed at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Citron Research to Discuss Valeant Pharma (VRX) at 12:30PM on Bloomberg
October 22, 2015 10:45 AM EDTCitron Research said it will be on Bloomberg TV at 12:30PM ET to discuss Valeant Pharma (NYSE: VRX) which follows yesterday's scathing report and drastic sell-off.
Bloomberg's live feed can be found here:... More
Valeant Pharma (VRX) Resumes Free-Fall; Down 15%
October 22, 2015 9:44 AM EDTValeant Pharma (NYSE: VRX) is back testing the $100 level again. Shares down 15% currently.
Today's BMO Capital downgrade, highlighted earlier, is certainly not helping.
... MoreDeutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating
October 22, 2015 9:37 AM EDTDeutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.
Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More
BMO Capital Downgrades Valeant Pharmaceuticals (VRX) to Market Perform; Cannot Defend the Specialty Pharmacy Structure
October 22, 2015 7:00 AM EDTBMO Capital downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Market Perform with a price target of $141.00, saying they cannot defend the specialty pharmacy structure.
Analyst Alex Arfaei commented, "Based on our understanding, ~10% of Valeants revenues come from specialty pharmacies. While other companies also use specialty pharmacies, the structure of Valeants network seems different. In... More
